Amputation

Vascular Surgeons are Embracing the Future of Peripheral Artery Disease (PAD) Treatment by Transitioning to Outpatient Procedures

Thursday, September 23, 2021 - 1:00pm

Dr. Correa joins three other Vascular Surgeons who have left their practices in the last year and a half to join Modern Vascular, joining one in St. Louis and two in Texas.

Key Points: 
  • Dr. Correa joins three other Vascular Surgeons who have left their practices in the last year and a half to join Modern Vascular, joining one in St. Louis and two in Texas.
  • Dr. Correa is not alone among vascular surgeons; four of the last seven Managing Physicians to come to Modern Vascular have also been Vascular Surgeons.
  • Modern Vascular clinics specialize in the treatment of peripheral artery disease (PAD) through below-the-knee and below-the-ankle and pedal endovascular arterial reconstruction.
  • Modern Vascular procedures are also an important step in avoiding future limb amputation and extending life expectancy in diabetic, cardiovascular, and peripheral artery disease patients.

Study Provides New Tool to Assess Amputation Risk Following Popliteal Vascular Injury

Wednesday, September 22, 2021 - 12:40pm

OBanion states, The aim of the present study, unlike the older systems, was to provide an easy to use scoring system that could be used to preoperatively and effectively risk stratify patients with traumatic popliteal vascular injuries for major amputation.

Key Points: 
  • OBanion states, The aim of the present study, unlike the older systems, was to provide an easy to use scoring system that could be used to preoperatively and effectively risk stratify patients with traumatic popliteal vascular injuries for major amputation.
  • This study confirms that patients with popliteal vascular injuries are at significant risk for amputation.
  • The POPSAVEIT tool is a valuable tool to assess this risk as soon as the patient enters the emergency room.
  • The Society for Vascular Surgery is the leading not-for-profit, professional medical society on establishing causes and treatments for vascular disease.

Adventist HealthCare Rehabilitation Welcomes New Facility Dog to Inpatient Therapy

Tuesday, September 21, 2021 - 11:00am

SILVER SPRING, Md., Sept. 21, 2021 /PRNewswire/ -- Adventist HealthCare Rehabilitation today announces its newest employee, an adorable four-legged friend named Peru.

Key Points: 
  • SILVER SPRING, Md., Sept. 21, 2021 /PRNewswire/ -- Adventist HealthCare Rehabilitation today announces its newest employee, an adorable four-legged friend named Peru.
  • The 3-year-old Golden Retriever serves as the inpatient rehabilitation hospital's first facility dog, trained by Canine Companions, to support her handler, rehabilitation psychologist, Heather Tropiano, Psy.D.
  • Adventist HealthCare Rehabilitation is a faith-based network of inpatient rehabilitation hospitals and outpatient rehabilitation clinics that span Montgomery County, Maryland.
  • Adventist HealthCare Rehabilitation inpatient hospitals are fully accredited by The Joint Commission, with Commission on Accreditation of Rehabilitation Facilities (CARF) accredited specialty programs for amputations, brain injury, spinal cord injury, and stroke.For more information visit AdventistHealthCare.com .

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

In Honor of National Peripheral Artery Disease (PAD) Awareness Month, THE SAGE GROUP Comments on the Costs and Consequences of the Amputation Lottery

Tuesday, September 14, 2021 - 2:41pm

It is commonly believed that amputation costs the hospital less than revascularization procedures.

Key Points: 
  • It is commonly believed that amputation costs the hospital less than revascularization procedures.
  • Although initial procedure costs are similar, total amputation costs including the costs of in-hospital mortality, morbidity and revision procedures are higher than those of either bypass or endovascular.
  • Treatment with MA (above-the-knee amputation or below-the-knee amputation) rather than revascularization significantly increases the economic burden of critical limb ischemia (CLI).
  • THE SAGE GROUP, a research and consulting company, specializes in peripheral vascular disease, including venous disease, PAD and CLI, as well as the economic costs of these diseases.

Vibrato Medical Closes $4M Series A Funding Round and Receives $1.5M NIH Grant

Tuesday, September 14, 2021 - 1:00pm

Our goal is to become the preferred therapeutic system for patients with reduced tissue perfusion, such as those with PAD and CLI.

Key Points: 
  • Our goal is to become the preferred therapeutic system for patients with reduced tissue perfusion, such as those with PAD and CLI.
  • Our recent funding puts us on the path towards that vision, said Juliana Elstad, CEO at Vibrato.
  • We are excited to partner with Vibrato Medical on the development of a truly novel technology to treat this terrible condition.
  • The company plans to use Series A funding and its $1.5M NIH grant for its pilot clinical study, to design and build its second-generation device, and advance its intellectual property.

Adaptive Phage Therapeutics Highlights the Publication of a Case Study of Investigational Phage Therapy for an Antibiotic-Resistant Bacterial Infection in a Child

Thursday, September 9, 2021 - 1:00pm

Surgical debridement and hardware removal, as well as three months of intravenously administrated antibiotics failed to stop the pernicious infection.

Key Points: 
  • Surgical debridement and hardware removal, as well as three months of intravenously administrated antibiotics failed to stop the pernicious infection.
  • The investigational phage therapy was prepared by APT and utilized in an effort to prevent the amputation of the patients infected lower leg.
  • The authors state a significant therapeutic effect was observed within two weeks of starting the adjunctive phage therapy.
  • In-vitro activity of multiple phage strain candidates were assessed by means of APTs PhageBank Susceptibility Test (PST) to determine the clinically relevant selection.

Shirley Ryan AbilityLab Mourns the Passing of Joanne C. Smith, MD, President & CEO

Tuesday, September 7, 2021 - 7:00pm

CHICAGO, Sept. 7, 2021 /PRNewswire/ -- Shirley Ryan AbilityLab (formerly Rehabilitation Institute of Chicago) today announced the untimely passing of Joanne C. Smith, MD, president and CEO.

Key Points: 
  • CHICAGO, Sept. 7, 2021 /PRNewswire/ -- Shirley Ryan AbilityLab (formerly Rehabilitation Institute of Chicago) today announced the untimely passing of Joanne C. Smith, MD, president and CEO.
  • Dr. Smith died following treatment for cancer, which she battled privately while continuing to fully lead Shirley Ryan AbilityLab.
  • "We are deeply saddened by the loss of our friend and leader, Dr. Joanne Smith," said M. Jude Reyes, board chair.
  • In 2006, a few years after earning her MBA from the University of Chicago, she became president and CEO.

HSS Study Finds Bone-Anchored Prosthetics Improve Mobility and Quality of Life for Leg Amputees

Tuesday, September 7, 2021 - 4:00pm

But the agency allows a limited number of patients to receive the implants through humanitarian exceptions.

Key Points: 
  • But the agency allows a limited number of patients to receive the implants through humanitarian exceptions.
  • "This is a disruptive technology to improve the life quality of amputees," said study co-author S. Robert Rozbruch, MD , Chief of the Limb Lengthening andComplex ReconstructionService and Director of the Limb Salvage and Amputation Reconstruction Center at HSS.
  • "With a direct skeletal connection of the prosthetic limb, amputees report big improvements in function, comfort, balance, proprioception and even emotional connection with their limb."
  • Researchers found that scores across all domains of the QTFA improved significantly throughout the study period.

Omeza Receives FDA Clearance for Omeza® Collagen Matrix

Thursday, September 2, 2021 - 5:36pm

SARASOTA, Fla., Sept. 2, 2021 /PRNewswire/ --Omeza, a skin science company, announced today the U.S. Food and Drug Administration (FDA) cleared Omeza Collagen Matrix through the FDA 510(k) premarket notification process.

Key Points: 
  • SARASOTA, Fla., Sept. 2, 2021 /PRNewswire/ --Omeza, a skin science company, announced today the U.S. Food and Drug Administration (FDA) cleared Omeza Collagen Matrix through the FDA 510(k) premarket notification process.
  • Omeza Collagen Matrix is Omeza's first Rx product, and the first drug/device combination matrix of its kind for chronic wound care.
  • Omeza Collagen Matrix is the first drug/device combination matrix of its kind for chronic wound care.
  • Omeza Collagen Matrix (OCM) is a wound care matrix comprised of hydrolyzed fish collagen infused with cod liver oil, which acts as an anhydrous skin protectant, and other plant-derived oils and waxes.